Alzheimer's Disease - Imperial CA

Summary:

A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, 52-WEEK STUDY EVALUATING THE SAFETY AND EFFICACY OF SIMUFILAM 100 MG TABLETS IN SUBJECTS WITH MILD-TO­MODERATE ALZHEIMER'S DISEASE 

-Ages 50-87

-Be able to see  and hear with no major issues in order to complete assessments in the office during the study

-Not being a smoker or chewing tobacco for at least 3 years

-Participant must have have a study partner/caregiver (family, friend or paid) who spends frequent and sufficient contact with the participant at least 10 hours or more per week, who can provide accurate information regarding the study subject's cognitive and functional abilities, will be able to attend all study visits and complete all procedures during the study as required

-Participant must not reside in a skilled nursing facility requring 24 hour care, they must live at home, with family or an independent or senior apartment type setting or residence.

-English and/or Spanish speaking participants, study partner/caregivers can participate

Qualified Participants May Receive:

-All study related care will be provided free at no cost including the study medication

-Participant will be reimbursement $100 for their time and travel for each study visit and the study partner/caregiver will be reimbursed $60 for their time and travel for each study visit.

-Transportation may be provided for each study visit at no cost